<DOC>
	<DOCNO>NCT01231438</DOCNO>
	<brief_summary>Patients reduce renal function normally develop hyperparathyroidism , turn associate increase cardiovascular risk de-calcification . Hyperparathyroidism may enhance increase level FGF23 often see early stage renal failure . This pilot study investigate FGF23-lowering effect early initiation treatment phosphate binder versus active vitamin D open crossover design .</brief_summary>
	<brief_title>Treatment Early Stage Renal Failure With Active Vitamin D Phosphate Binder .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Renal failure stage 3B 25 ( OH ) vitamin D level 50 nmol/l Age 18 year Written consent Major surgery previous 6 month Myocardial infarct previous 6 month Unstable heart failure Ongoing treatment malignancy History frequent infection Pregnancy Ongoing treatment steroid , lithium biphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Renal failure stage 3B</keyword>
</DOC>